CPD-002

• UNSPSC Description:

  CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis[1].

• Target Antigen:

  VEGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cpd-002.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CNC(C1=CC=CC=C1SC2=CC3=C(C(NC(C)=O)=NN3)C=C2)=O

• Molecular Weight:

  340.40

• References & Citations:

  [1]Jiang F, et al., CPD-002, a novel VEGFR2 inhibitor, relieves rheumatoid arthritis by reducing angiogenesis through the suppression of the VEGFR2/PI3K/AKT signaling pathway. Int Immunopharmacol. 2024 Apr 20;131:111850.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2617376-08-4